Keyword: Flexus Biosciences
The studies are the latest dominoes to fall following the failure of Incyte’s rival IDO drug to move the needle in a pivotal trial.
FLX Bio has boosted its cash supplies with a new $60 million series C round as it starts dosing for its first cancer test.
The heavily pretreated bladder cancer data suggest the cocktail can hold its own against a combination of rival drugs from Incyte and Merck.
The decision positions the Celgene-backed cancer immunotherapy biotech to move oral small molecule FLX475 into the clinic later this year.
Fresh off the $1.25 billion Flexus sale, Terry Rosen is aiming to build a major immuno-oncology biopharma from the ground up with upstart Arcus Biosciences.
Former Flexus execs are together again in another effort to create novel small molecule oncology candidates that are potentially single agent therapies.